caa a22 4500 469026413 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962549 doi (NATIONALLICENCE)springer-10.1007/BF01962549 Wiltink E. Department of Pharmacy, Academic Medical Centre, Meibergdreef 9, 1105, AZ Amsterdam, the Netherlands aut Future prospects in antiviral therapy [Elektronische Daten] [E. Wiltink] Two important stumbling blocks to the development of effective and nontoxic antiviral drugs are the intracellular localization of the virus and the fact that a virus uses host cell functions to multiply. Therefore, new antiviral drugs must act on a virus-specific function. Most currently available useful antiviral drugs are the result of compound screening of large numbers of possible agents. Advances in our understanding of the molecular biology and biochemistry of the viral multiplication cycle and new laboratory techniques for determining the molecular sites of action have now made it possible to develop and screen new antiviral drugs in a more purposeful manner. Another possible option in antiviral therapy is combination therapy using drugs that enhance the therapeutic effect or diminish side-effects. The most promising new antiviral drugs are discussed according to the different steps they affect in the viral multiplication process. Combination therapy is also reviewed. Royal Dutch Association for Advancement of Pharmacy, 1992 Antiviral drugs nationallicence Future prospects nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 268-274 0031-6911 14:4<268 1992 14 11096 https://doi.org/10.1007/BF01962549 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962549 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Wiltink E. Department of Pharmacy, Academic Medical Centre, Meibergdreef 9, 1105, AZ Amsterdam, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 268-274 0031-6911 14:4<268 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer